Characterization of anti-Toxoplasma activity of SDZ 215-918, a cyclosporin derivative lacking immunosuppressive and peptidyl-prolyl- isomerase-inhibiting activity: Possible role of a P glycoprotein in Toxoplasma physiology

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 9, 1997, Pages 1859-1866

  Silverman, Jared A ^a,c   Hayes, Mary Lou ^b   Luft, Benjamin J ^b   Joiner, Keith A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CYCLOHEXIMIDE; CYCLOPHILIN; CYCLOSPORIN A; CYCLOSPORIN A DERIVATIVE; CYCLOSPORIN H; DIHYDROCYCLOSPORIN A; GLYCOPROTEIN P; METHIONINE; MYCOPHENOLIC ACID; PYRIMETHAMINE; RHODAMINE 123; SDZ 215918; SDZ 216070; SDZ 217383; UNCLASSIFIED DRUG; URACIL; VALSPODAR; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TOXOPLASMA GONDII;

EID: 0030765061     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.9.1859     Document Type: Article

References (54)

1. Aebi, J. D., D. T. Deyo, C. Q. Sun, D. Guillaume, B. Dunlap, and D. H. Rich. 1990. Synthesis, conformation, and immunosuppressive activities of three analogues of cyclosporin A modified in the 1-position. J. Med. Chem. 33: 999-1009.
2. Beaman, M. H., R. E. McCabe, S.-Y. Wong, and J. S. Remington. 1995. Toxoplasma gondii, p. 2455-2475. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases. Churchill Livingstone, New York, N.Y.
3. Beckers, C. J. M., D. S. Roos, R. G. K. Donald, B. J. Luft, J. C. Schwab, Y. Cao, and K. A. Joiner. 1995. Inhibition of cytoplasmic and organellar protein synthesis in Toxoplasma gondii: implications for the target of macrolide antibiotics. J. Clin. Invest. 95:367-376.
4. Bell, A., B. Weroli, and R. M. Franklin. 1994. Roles of peptidyl-prolyl cis-trans isomerase and calcineurin in the mechanism of antimalarial action of cyclosporin A, FK506, and rapamycin. Biochem. Pharm. 48:495-503.
5. Bellamy, W. T. 1996. P-glycoprotein and multidrug resistance. Annu. Rev. Pharmacol. Toxicol. 36:161-183.
6. Blais, J., C. Tardif, and S. Chamberland. 1993. Effect of clindamycin on intracellular replication, protein synthesis, and infectivity of Toxoplasma gondii. Antimicrob. Agents Chemother. 37:2571-2577.
7. Bogdan, C., H. Streck, M. Rollingham, and W. Solbach. 1989. Cyclosporin A enhances elimination of intracellular L. major parasites by murine macrophages. Clin. Exp. Immunol. 75:141-146.
8. Bohme, M., M. Buchler, M. Muller, and D. Keppler. 1993. Differential inhibition by cyclosporins of primary-active ATP-dependent transporters in the hepatocyte canalicular membrane. FEBS Lett. 333:193-196.
9. Book, D. J., I. F. Dennis, P. R. Twentyman, R. J. Osborne, C. Laborte, S. Hensel, J. F. Smyth, M. H. Brampton, and N. M. Bleeker. 1996. Phase I study of etoposide with SDZ PSC-833 as modulator of multidrug resistance in patients with cancer. J. Clin. Oncol. 14:610-618.
10. Choi, I., and R. B. Mikkelsen. 1990. Plasmodium falciparum: ATP/ADP transport across the parasitophorous vacuole and plasma membranes. Exp. Parasitol. 71:452-462.
11. Cornwell, M. M., M. M. Gottesman, and I. H. Pastan. 1986. Increased vinblastine binding to membrane vesicles from multidrug-resistant KB cells. J. Biol. Chem. 261:7921-7928.
12. Couvreur, G., A. Sadak, B. Fortier, and J. F. Dubremetz. 1988. Surface antigens of Toxoplasma gondii. Parasitology 97:1-10.
13. Dobrowolski, J. M., and L. D. Sibley. 1996. Toxoplasma invasion of mammalian cells is powered by the actin cytoskeleton of the parasite. Cell 84: 933-939.
14. Donald, R. G. K., D. Carter, B. Ullman, and D. S. Roos. 1996. Insertional tagging cloning and expression of the Toxoplasma gondii hypoxanthine-xanthine-guanine phosphoribosyl transferase gene: characterization of a new genetic marker for stable transformation. J. Biol. Chem. 271:14010-14019.
15. Dubremetz, J. F. 1995. Toxoplasma gondii: cell biology update, p. 345-368. In J. C. Boothroyd and R. Komunieck (ed.), Molecular approaches to parasitology. Wiley-Liss, New York, N.Y.
16. Efferth, T., H. Lohrke, and M. Volm. 1989. Recpiprocal correlation between expression of P-glycoprotein and accumulation of rhodamine 123 in human tumors. Anticancer Res. 9:1633-1637.
17. Emmer, G., M. A. Grassberger, G. Schulz, D. Boesch, C. Gaveriaux, and F. Loor. 1994. Derivatives of a novel cyclopeptolide. 2. Synthesis, activity against multidrug resistance in CHO and KB cells in vitro, and structure-activity relationships. J. Med. Chem. 37:1918-1928.
18. Endo, T., and K. Yagita. 1990. Effect of extracellular ions on motility and cell entry in Toxoplasma gondii. J. Protozool. 37:133-138.
19. Ferry, D. R., H. Traunecher, and D. J. Kerr. 1996. Clinical trials of P-glycoprotein reversal in solid tumours. Eur. J. Cancer 32A: 1070-1081.
20. Germann, U. A. 1996. P-glycoprotein: a mediator of multidrug resistance in tumour cells. Eur. J. Cancer 32A:927-944.
21. Gueiros-Filho, F. J., J. P. Viola, F. C. Gomes, M. Farina, U. Lins, A. L. Bertho, D. F. Wirth, and U. G. Lopes. 1995. Leishmania amazonensis: multidrug resistance in vinblastine-resistant promastigotes is associated with rhodamine 123 efflux, DNA amplification, and RNA overexpression of a Leishmania mdr1 gene. Exp. Parasitol. 81:480-490.
22. Haynes, M., L. Fuller, D. H. Haynes, and J. Miller. 1985. Cyclosporin partitions into phospholipid vesicles and disrupts membrane architecture. Immunol. Lett. 11:343-349.
23. High, K. P. 1994. The immunosuppressive and antimicrobial activities of cyclosporin A, FK506, and rapamycin. Transplantation 57:1689-1700.
24. High, K. P., and R. E. Handschumacher. 1992. Immunity, microbial pathogenesis, and immunophilins: finding the keys, now where are the locks? Infect. Agents Dis. 1:121-135.
25. High, K. P., K. A. Joiner, and R. E. Handschumacher. 1994. Isolation, characterization, and amino acid sequence of the two major cyclosporin binding proteins of Toxoplasma gondii. J. Biol. Chem. 269:9105-9112.
26. Holfels, E., J. McAuley, D. Mack, W. K. Milhous, and R. McLeod. 1994. In vitro effects of artemisinin ether, cycloguanil hydrochloride (alone and in combination with sulfadiazine), quinine sulfate, mefloquine, primaquine phosphate, trifluoperazine hydrochloride, and verapamil on Toxoplasma gondii. Antimicrob. Agents Chemother. 38:1392-1396.
27. Joiner, K. A., S. A. Fuhrman, H. M. Miettinen, L. H. Kasper, and I. Mellman. 1990. Toxoplasma gondii: fusion competence of parasitophorous vacuoles in Fc receptor-transfected fibroblasts. Science 249:641-646.
28. Kofron, J. L., P. Kuzmic, V. Kishore, G. Colon-Bonilla, and D. H. Rich. 1991. Determination of kinetic constants for peptidyl-prolyl cis-trans isomerases by an improved spectrophotometric assay. Biochemistry 30:6127-6134.
29. Kunz, J., and M. N. Hall. 1993. Cyclosporin A, FK506, and rapamycin: more than just immunosuppression. Trends Biochem. Sci. 18:334-338.
30. Mack, R. G., and R. McLeod. 1984. New micromethod to study the effect of antimicrobial agents on Toxoplasma gondii: comparison of sulfadoxine and sulfadiazine individually and in combination with pyrimethamine and study of clindamycin, metronidazole, and cyclosporin A. Antimicrob. Agents Chemother. 26:26-30.
31. Maurer, G. 1985. Metabolism of cyclosporine. Transplant. Proc. 17(Suppl. 1):19-26
32. McCabe, R. C., B. T. Luft, and J. S. Remington. 1986. The effects of cyclosporine on Toxoplasma gondii in vivo and in vitro. Transplantation 41:611-615.
33. Mineo, J. R., and L. H. Kasper. 1994. Attachment of Toxoplasma gondii to host cells involves major surface protein, SAG-1 (P30). Exp. Parasitol. 79: 11-20.
34. Morisaki, J. H., J. E. Heuser, and L. D. Sibley. 1995. Invasion of Toxoplasma gondii occurs by active penetration of the host cell. J. Cell Sci. 108:2457-2464.
35. Nickell, S. P., L. W. Scheibel, and G. A. Cole. 1982. Inhibition by cyclosporin A of rodent malaria in vivo and human malaria in vitro. Infect. Immun. 37:1093-1100.
36. Ossorio, P. N., J.-F. Dubremetz, and K. A. Joiner. 1994. A soluble secretory protein of the intracellular parasite Toxoplasma gondii associates with the parasitophorous vacuole membrane through hydrophobic interactions. J. Biol. Chem. 269:15350-15357.
37. Pfefferkorn, E. R., R. F. Nothnagel, and S. E. Borotz. 1992. Parasiticidal effect of clindamycin on Toxoplasma gondii grown in cultured cells and selection of a drug-resistant mutant. Antimicrob. Agents Chemother. 36: 1091-1096.
38. Pfefferkorn, E. R., and L. C. Pfefferkorn. 1977. Specific labeling of intracellular Toxoplasma gondii with uracil. J. Protozool. 24:449-453.
39. Price, E. R., M. Jin, D. Lim, S. Pati, C. T. Walsh, and F. D. McKeon. 1994. Cyclophilin B trafficking through the secretory pathway is altered by binding of cyclosporin A. Proc. Natl. Acad. Sci. USA 91:3931-3935.
40. Ruetz, S., and P. Gros. 1994. Phosphatidylcholine translocase: a physiological role for the mdr2 gene. Cell 77:1071-1081.
41. Ryning, F. W., and J. S. Remington. 1978. Effect of cytochalasin D on Toxoplasma gondii cell entry. Infect. Immun. 20:739-743.
42. Scheper, R. J., J. W. Bulte, J. G. Brakkee, J. J. Quak, E. van der Schoot, A. J. Balm, C. J. Meijer, H. J. Broxterman, C. M. Kuiper, J. Lankelma, and H. M. Pinedo. 1988. Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multidrug-resistance. Int. J. Cancer. 42:389-394.
43. Schinkel, A. H., C. A. Mol, E. Wagenaar, L. van Deemter, J. J. Smit, and P. Borst. 1995. Multidrug resistance and the role of P-glycoprotein knockout mice. Eur. J. Cancer. 31A:1295-1298.
44. Schrieber, S. L. 1992. Immunophilin-sensitive protein phosphatase action in cell signalling pathways. Cell 70:365-368.
45. Schwab, J. C., M. A. Affifi, G. Pizzorno, R. E. Handshumacher, and K. A. Joiner. 1995. Toxoplasma gondii tachyzoitcs possess an unusual plasma membrane adenosine transporter. Mol. Biochem. Parasitol. 70:59-69.
46. Silverman, J. A., and K. A. Joiner. 1997. Toxoplasma/host-cell interactions, p. 313-338. In S. Kaufmann (ed.), Host response to intracellular pathogens. R. G. Landes Company, Austin, Tex.
47. Tomavo, S., V. Wyls, and C. Torusel. 1996. Targeted disruption of P43 gene of Toxoplasma gondii reduces attachment to host cells and invasion. In meeting abstracts of the Toxoplasma Workshop.
48. Twentyman, P. R. 1992. Cyclosporins as drug resistance modifiers. Biochem. Pharm. 43:109-117.
49. Ullman, B. 1995. Multidrug resistance and P-glycoproteins in parasitic protozoa. J. Bioenerg. Biomembr. 27:77-84.
50. van Helvoort, A., A. J. Smith, H. Sprong, I. Fritzsche, A. H. Schinkel. P. Borst, and G. van Meer. 1996. MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 87:507-517.
51. VonWartburg, A., and R. Traber. 1986. Chemistry of the natural cyclosporin metabolites. Prog. Allergy 38:28-35.
52. Wenger, R. 1986. Cyclosporine and analogues: structural requirements for immunosuppressive activity. Transplant. Proc. 18(Suppl. 5):213-218.
53. Wenger, R. Personal communication.
54. Werk, R., and W. Bommer. 1980. Toxoplasma gondii: membrane properties of active energy-dependent invasion of host cells. Tropenmed. Parasitol. 31:417-420.